Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Capricor Therapeutics Inc CAPR

Healthcare Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product... see more

Recent & Breaking News (NDAQ:CAPR)

Capricor Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire December 2, 2024

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

GlobeNewswire November 20, 2024

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2024

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

GlobeNewswire November 12, 2024

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

GlobeNewswire November 5, 2024

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 18, 2024

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

GlobeNewswire October 17, 2024

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire October 16, 2024

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

GlobeNewswire October 11, 2024

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire October 9, 2024

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

GlobeNewswire October 4, 2024

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

GlobeNewswire September 24, 2024

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

GlobeNewswire September 23, 2024

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire September 17, 2024

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

GlobeNewswire September 6, 2024

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2024

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

GlobeNewswire July 31, 2024

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

GlobeNewswire July 1, 2024

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

GlobeNewswire June 28, 2024

CORRECTION: Capricor Therapeutics

GlobeNewswire June 25, 2024